<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nmp</journal-id><journal-title-group><journal-title xml:lang="ru">Журнал им. Н.В. Склифосовского «Неотложная медицинская помощь»</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Sklifosovsky Journal "Emergency Medical Care"</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2223-9022</issn><issn pub-type="epub">2541-8017</issn><publisher><publisher-name>“N.V. Sklifosovsky Research Institute for Emergency Medicine”</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.23934/2223-9022-2025-14-3-499-510</article-id><article-id custom-type="elpub" pub-id-type="custom">nmp-2202</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Использование биомаркеров для принятия решения о применении селективной гемосорбции липополисахаридов у пациентов с сепсисом и септическим шоком</article-title><trans-title-group xml:lang="en"><trans-title>Biomarkers for Predicting the Use of Selective Hemosorption of Lipopolysaccharides in Sepsis and Septic Shock</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7802-2283</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рей</surname><given-names>С. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Rey</surname><given-names>S. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Рей Сергей Игоревич, доцент, кандидат медицинских наук, старший научный сотрудник отдела неотложной хирургии, эндоскопии и интенсивной терапии,</p><p>129010, Москва, Большая Сухаревская пл., д. 3</p></bio><bio xml:lang="en"><p>Sergey I. Rey, Associate Professor, Candidate of Medical Sciences, Senior Researcher, Department of Emergency Surgery, Endoscopy and Intensive Care, </p><p>Bolshaya Sukharevskaya Sq. 3, Moscow, 129090</p></bio><email xlink:type="simple">reysi@sklif.mos.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3726-3256</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бердников</surname><given-names>Г. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Berdnikov</surname><given-names>G. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бердников Геннадий Анатольевич, кандидат медицинских наук, старший научный сотрудник отдела неотложной хирургии, эндоскопии и интенсивной терапии,</p><p>129010, Москва, Большая Сухаревская пл., д. 3</p></bio><bio xml:lang="en"><p>Gennady A. Berdnikov, Candidate of Medical Sciences, Senior Researcher, Department of Emergency Surgery, Endoscopy and Intensive Care,</p><p>Bolshaya Sukharevskaya Sq. 3, Moscow, 129090</p></bio><email xlink:type="simple">polina1905@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8897-7523</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Боровкова</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Borovkova</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Боровкова Наталья Валерьевна, доцент, доктор медицинских наук, заведующая научным отделением биотехнологий и трансфузиологии,</p><p>129010, Москва, Большая Сухаревская пл., д. 3</p></bio><bio xml:lang="en"><p>Natalia V. Borovkova, Associate Professor, Doctor of Medical Sciences, Head, Scientific Department of Biotechnology and Transfusiology, </p><p>Bolshaya Sukharevskaya Sq. 3, Moscow, 129090</p></bio><email xlink:type="simple">borovkovanv@sklif.mos.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9612-6705</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Годков</surname><given-names>М. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Godkov</surname><given-names>M. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Годков Михаил Андреевич, доктор медицинских наук, заведующий научным отделом лабораторной диагностики,</p><p>129010, Москва, Большая Сухаревская пл., д. 3</p></bio><bio xml:lang="en"><p>Mikhail A. Godkov, Doctor of Medical Sciences, Head, Scientific Department of Laboratory Diagnostics,</p><p>Bolshaya Sukharevskaya Sq. 3, Moscow, 129090</p></bio><email xlink:type="simple">godkovma@sklif.mos.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3349-0451</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Клычникова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Klychnikova</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Клычникова Елена Валерьевна, кандидат медицинских наук, заведующая научной клинико-биохимической лабораторией экстренных методов исследования,</p><p>129010, Москва, Большая Сухаревская пл., д. 3</p></bio><bio xml:lang="en"><p>Elena V. Klychnikova, Candidate of Medical Sciences, Head, Scientific Clinical and Biochemical Laboratory of Emergency Research Methods, </p><p>Bolshaya Sukharevskaya Sq. 3, Moscow, 129090</p></bio><email xlink:type="simple">klychnikovaev@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-1063-9492</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кузнецова</surname><given-names>Т. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Kuznetsova</surname><given-names>T. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кузнецова Татьяна Евгеньевна, врач клинической лабораторной диагностики лаборатории клинической иммунологии,</p><p>129010, Москва, Большая Сухаревская пл., д. 3</p></bio><bio xml:lang="en"><p>Tatyana E. Kuznetsova ,Doctor of Clinical Laboratory Diagnostics, Laboratory of Clinical Immunology,</p><p>Bolshaya Sukharevskaya Sq. 3, Moscow, 129090</p></bio><email xlink:type="simple">kuznetsovate@sklif.mos.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-5844-5522</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Максимов</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Maksimov</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Максимов Алексей Анатольевич, руководитель отдела ГХ-МС,</p><p>129110, Москва, ул. Щепкина, д. 58, стр. 3</p></bio><bio xml:lang="en"><p>Aleksey A. Maksimov, Head, GC-MS Department, </p><p>Shchepkina Str. 58, bldg. 3, Moscow, 129110</p></bio><email xlink:type="simple">maksimof.a.a@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4071-1099</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тюрин</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Tyurin</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Тюрин Игорь Александрович, заведующий химико-токсикологической лабораторией,</p><p>129010, Москва, Большая Сухаревская пл., д. 3</p></bio><bio xml:lang="en"><p>Igor A. Tyurin, Head, Chemical Toxicology Laboratory, </p><p>Bolshaya Sukharevskaya Sq. 3, Moscow, 129090</p></bio><email xlink:type="simple">tyurinia@sklif.mos.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ГБУЗ «Научно-исследовательский институт скорой помощи им. Н.В. Склифосовского ДЗМ»<country>Россия</country></aff><aff xml:lang="en">N.V. Sklifosovsky Research Institute for Emergency Medicine<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">ООО «Лаборатория ЕвроТест»<country>Россия</country></aff><aff xml:lang="en">EuroTest Laboratory<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>24</day><month>09</month><year>2025</year></pub-date><volume>14</volume><issue>3</issue><fpage>499</fpage><lpage>510</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Рей С.И., Бердников Г.А., Боровкова Н.В., Годков М.А., Клычникова Е.В., Кузнецова Т.Е., Максимов А.А., Тюрин И.А., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Рей С.И., Бердников Г.А., Боровкова Н.В., Годков М.А., Клычникова Е.В., Кузнецова Т.Е., Максимов А.А., Тюрин И.А.</copyright-holder><copyright-holder xml:lang="en">Rey S.I., Berdnikov G.A., Borovkova N.V., Godkov M.A., Klychnikova E.V., Kuznetsova T.E., Maksimov A.A., Tyurin I.A.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.jnmp.ru/jour/article/view/2202">https://www.jnmp.ru/jour/article/view/2202</self-uri><abstract><sec><title>Актуальность</title><p>Актуальность. Сепсис и септический шок продолжают оставаться жизнеугрожающими состояниями с высокой летальностью, достигающей при наличии эндотоксемии 70%. Экстракорпоральное удаление липополисахаридов (ЛПС) может улучшить результаты лечения.</p></sec><sec><title>Цель работы</title><p>Цель работы. Оценить эффективность использования группы биомаркеров при выборе показаний для проведения селективной гемосорбции липополисахаридов (ЛПС-ГС) у пациентов с сепсисом и септическим шоком.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Обследованы 22 пациента (12 мужчин и 10 женщин), находившихся на лечении в НИИ скорой помощи им. Н.В. Склифосовского ДЗМ с апреля 2022 по ноябрь 2023 года. Пациентов обследовали в течение 72 часов после развития сепсиса. При развитии сепсиса или септического шока, при уровне активности эндотоксина (endotoxin activity assay — ЕАА) ≥0,6 11 пациентам выполнили селективную гемосорбцию липополисахаридов. Значения перед гемоперфузией анализировали в группе 1 (11 точек), если ЛПС-ГС не применялась — в группе 2 (22 точки).</p></sec><sec><title>Результаты</title><p>Результаты. Концентрация β-гидроксимиристиновой кислоты (β-Hydroxymyristic acid — β-HMA) у здоровых добровольцев составила 2,95 (1,52;5,08) нг/мл, а у пациентов с сепсисом и септическим шоком 7,44 (4,50; 15,68) нг/мл (р=0,0001). Уровень ЕАА был выше в группе 1 (0,780 у.е.) по сравнению с группой 2 (0,425 у.е.), р=0,019. Выявлены различия 1-й и 2-й групп по уровню С-реактивного белка (СРБ): 290,0 и 166,5 мг/л соответственно (р=0,016). Процентное содержание лимфоцитов (CD95+) было ниже в группе 1 по сравнению с группой 2: 24,8% и 44,2% соответственно (р=0,04). Тяжесть органной дисфункции по шкале SOFA значимо коррелировала с уровнем β-HMA, коэффициент корреляции Спирмена r составил 0,386, выявлена умеренная корреляция между уровнем β-HMA и ИЛ-6 (r=0,638), ЕАА и СРБ (r=0,485), отрицательная корреляция CD95+ с уровнем ИЛ-6 и СРБ.</p></sec><sec><title>Выводы</title><p>Выводы. 1. Уровень β-HMA у пациентов с сепсисом и септическим шоком в 2,5 раза статистически значимо превышает значения у здоровых добровольцев (р=0,0001). При ROC-анализе AUC составила 0,817 (95% ДИ [0,702; 0,933], р=0,0001), точка отсечения — 3,26 нг/мл. 2. Использование пороговых значений ЕАА не менее 0,6 у.е. позволило выявить пациентов, требующих проведения селективной гемосорбции липополисахаридов со статистически значимыми различиями уровня активности эндотоксина (р=0,019) и С-реактивного белка (р=0,016). При этом в группе высокого ЕАА отмечалась тенденция к увеличению абсолютного значения уровня липополисахаридов, тестируемого по β-HMA, тяжести органной дисфункции по шкале SOFA, достигающей 13 баллов, по сравнению с 9,5 баллами в группе низкого ЕАА. 3. В группе с высоким ЕАА установлено статистически значимое снижение уровня в крови CD95+ лимфоцитов (р=0,033), что вместе с тенденцией к более низким значениям экспрессии HLA-DR на моноцитах может указывать на развитие у данных пациентов иммунопаралича и дисрегуляции иммунной системы. 4. Уровень в крови β-HMA коррелировал с тяжестью органной дисфункции по шкале SOFA и показателями интерлейкина-6. ЕАА положительно коррелирует с уровнем С-реактивного белка и отрицательно коррелирует с уровнем интерлейкина-6. Установлена положительная корреляция интерлейкина-6 с уровнем С-реактивного белка и отрицательная с уровнем CD95+ лимфоцитов. Уровень С-реактивного белка отрицательно коррелирует с таковым CD95+ лимфоцитов.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Abstract</title><p>Abstract. Sepsis and septic shock are one of the most life-threatening complications with high mortality, reaching 70% in the presence of endotoxemia. Extracorporeal removal of lipopolysaccharides (LPS) can improve treatment outcomes.</p></sec><sec><title>Aim</title><p>Aim. To evaluate the effectiveness of a group of biomarkers for predicting the use of selective hemosorption of lipopolysaccharides in patients with sepsis and septic shock.</p></sec><sec><title>Material and Methods</title><p>Material and Methods. The study included 22 patients (12 men and 10 women) who were treated at the N.V. Sklifosovsky Research Institute for Emergency Medicine from April 2022 to November 2023. Patients were examined within 72 hours after the development of sepsis. In the case of sepsis or septic shock, with an endotoxin activity assay (EAA) ≥0.6, 11 patients underwent LPS-selective hemoperfusion (LPS-HP) procedures. The values before hemoperfusion were analyzed in Group 1 (11 points), if LPS-HP was not used — in Group 2 (22 points).</p></sec><sec><title>Results</title><p>Results. The concentration of β-hydroxymyristic acid (β-HMA) in healthy volunteers was 2.95 (1.52; 5.08) ng/ml, and in patients with sepsis and septic shock 7.44 (4.50; 15.68) ng/ml (p=0.0001). The level of EAA was higher in Group 1 (0.780) compared to Group 2 (0.425), p=0.019. Differences were found between Groups 1 and 2 in the level of CRP: 290.0 and 166.5 mg/l, respectively (p=0.016). The percentage of lymphocytes (CD95+) was lower in Group 1 compared to Group 2: 24.8 and 44.2%, respectively (p=0.04). The SOFA score significantly correlated with the β-HMA level, the Spearman correlation coefficient r was 0.386, a moderate correlation was found between the β-HMA level and IL-6 (r=0.638), EAA and CRP (r=0.485), a negative correlation of CD 95+ lymphocytes with the level of IL-6 and CRP.</p></sec><sec><title>Conclusion</title><p>Conclusion. 1. The β-HMA level in patients with sepsis and septic shock is 2.5 times higher than the values in healthy volunteers (p=0.0001). In the ROC analysis, AUC was 0.817 (95% CI 0.702; 0.933, p=0.0001), the cutoff point was 3.26 ng/ml. 2. Using the threshold values EAA≥0.6 c.u. allowed us to identify patients requiring LPS-selective hemoperfusion with statistically significant differences in the level of endotoxin activity (p=0.019) and CRP (p=0.016). At the same time, in the high EAA group, there was a tendency for an increase in the absolute value of the LPS level tested by β-HMA, the SOFA score was 13 points, compared with 9.5 points in the low EAA group. 3. In the high EAA group, a decrease in CD 95+ lymphocytes was established (p=0.033), which, together with a tendency towards lower values of HLA-DR expression on monocytes, may indicate the development of immunoparalysis and immune system dysregulation in these patients. 4. The β-HMA level correlated with the severity of organ dysfunction according to the SOFA score and IL-6 levels. EAA positively correlates with the level of CRP, and negatively correlates with IL-6. A positive correlation of IL-6 with CRP and a negative correlation with the level of CD 95+ lymphocytes were established. CRP negatively correlated with CD 95+ lymphocytes.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>сепсис</kwd><kwd>экстракорпоральная гемокоррекция</kwd><kwd>селективная гемосорбция липополисахаридов</kwd><kwd>эндотоксин</kwd><kwd>активность эндотоксина (ЕАА-тест)</kwd><kwd>β-гидроксимиристиновая кислота</kwd></kwd-group><kwd-group xml:lang="en"><kwd>sepsis</kwd><kwd>blood purification</kwd><kwd>selective hemosorption of lipopolysaccharides</kwd><kwd>endotoxin</kwd><kwd>endotoxin activity assay (EAA)</kwd><kwd>β-hydroxymyristic acid</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395:200–211. PMID: 31954465 https://doi.org/10.1016/S0140-6736(19)32989-7</mixed-citation><mixed-citation xml:lang="en">Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395:200–211. PMID: 31954465 https://doi.org/10.1016/S0140-6736(19)32989-7</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Liu YC, Yao Y, Yu MM, Gao YL, Qi AL, Jiang TY, et al. Frequency and mortality of sepsis and septic shock in China: a systematic review and meta-analysis. BMC Infectious Diseases. 2022;22(1):564. PMID: 35729526 https://doi.org/10.1186/s12879-022-07543-8</mixed-citation><mixed-citation xml:lang="en">Liu YC, Yao Y, Yu MM, Gao YL, Qi AL, Jiang TY, et al. Frequency and mortality of sepsis and septic shock in China: a systematic review and meta-analysis. BMC Infectious Diseases. 2022;22(1):564. PMID: 35729526 https://doi.org/10.1186/s12879-022-07543-8</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Vincent JL, Jones G, David S, Olariu E, Cadwell KK. Frequency and mortality of septic shock in Europe and North America: a systematic review and meta-analysis. Crit Care. 2019;23(1):196. PMID: 31151462 https://doi.org/10.1186/s13054-019-2478-6</mixed-citation><mixed-citation xml:lang="en">Vincent JL, Jones G, David S, Olariu E, Cadwell KK. Frequency and mortality of septic shock in Europe and North America: a systematic review and meta-analysis. Crit Care. 2019;23(1):196. PMID: 31151462 https://doi.org/10.1186/s13054-019-2478-6</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Seymour CW, Kennedy JN, Wang S, Chang CH, Elliott CF, Xu Z, et al. Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis. JAMA. 2019;321(20):2003–2017. PMID: 31104070 https://doi.org/10.1001/jama.2019.5791</mixed-citation><mixed-citation xml:lang="en">Seymour CW, Kennedy JN, Wang S, Chang CH, Elliott CF, Xu Z, et al. Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis. JAMA. 2019;321(20):2003–2017. PMID: 31104070 https://doi.org/10.1001/jama.2019.5791</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Kellum JA, Ronco C. The role of endotoxin in septic shock. Crit Care. 2023;27(1):400. PMID: 37858258 https://doi.org/10.1186/s13054-023-04690-5</mixed-citation><mixed-citation xml:lang="en">Kellum JA, Ronco C. The role of endotoxin in septic shock. Crit Care. 2023;27(1):400. PMID: 37858258 https://doi.org/10.1186/s13054-023-04690-5</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Adamik B, Smiechowicz J, Jakubczyk D, Kübler A. Elevated Serum PCT in Septic Shock with Endotoxemia Is Associated with a Higher Mortality Rate. Medicine (Baltimore). 2015;94(27):e1085. PMID: 26166090 https://doi.org/10.1097/MD.0000000000001085</mixed-citation><mixed-citation xml:lang="en">Adamik B, Smiechowicz J, Jakubczyk D, Kübler A. Elevated Serum PCT in Septic Shock with Endotoxemia Is Associated with a Higher Mortality Rate. Medicine (Baltimore). 2015;94(27):e1085. PMID: 26166090 https://doi.org/10.1097/MD.0000000000001085</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Hurley JC, Guidet B, Offenstad G, Maury E. Endotoxemia and mortality prediction in ICU and other settings: underlying risk and co-detection of gram negative bacteremia are confounders. Crit Care. 2012;16(4): R148. PMID: 22871090 https://doi.org/10.1186/cc11462</mixed-citation><mixed-citation xml:lang="en">Hurley JC, Guidet B, Offenstad G, Maury E. Endotoxemia and mortality prediction in ICU and other settings: underlying risk and co-detection of gram negative bacteremia are confounders. Crit Care. 2012;16(4): R148. PMID: 22871090 https://doi.org/10.1186/cc11462</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Лазанович В.А., Маркелова Е.В., Смирнов Г.А., Смолина Т.П. Клиническая значимость экспрессии Toll2, Toll4, CD14, HLA-DR на моноцитах у пациентов с сепсисом. Медицинская иммунология. 2015;17(3):221–228. https://doi.org/10.15789/1563-0625-2015-3-221-228</mixed-citation><mixed-citation xml:lang="en">Lazanovich VA, Markelova EV, Smirnov GA, Smolina TP. Clinical Significance of Toll2, Toll4, CD14, and HLA-DR Expression on the Monocytes in Patients With Sepsis. Medical Immunology (Russia). 2015;17(3):221–228. (In Russ.) https://doi.org/10.15789/1563-0625-2015-3-221-228</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801–810. PMID: 26903338 https://doi.org/10.1001/jama.2016.0287</mixed-citation><mixed-citation xml:lang="en">Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801–810. PMID: 26903338 https://doi.org/10.1001/jama.2016.0287</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Киров М.Ю., Кузьков В.В., Проценко Д.Н., Щеголев А.В., Бабаев М. А., Белоцерковский Б.З. и др. Септический шок у взрослых: клинические рекомендации Общероссийской общественной организации «Федерация анестезиологов и реаниматологов». Вестник интенсивной терапии им. А. И. Салтанова. 2023;(4):7–42. https://doi.org/10.21320/1818-474X-2023-4-7-42</mixed-citation><mixed-citation xml:lang="en">Kirov MY, Kuzkov VV, Protsenko DN, Shchegolev AV, Babaev MA, Belotserkovskiy BZ, et al. Septic shock in adults: guidelines of the All-Russian public organization “Federation of Anesthesiologists and Reanimatologists”. Annals of Critical Care. 2023;(4):7–42. (in Russ.) https://doi.org/10.21320/1818-474X-2023-4-7-42</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Dellinger RP, Bagshaw SM, Antonelli M, Foster DM, Klein DJ, Marshall JC, et al.; EUPHRATES Trial Investigators. Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients with Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial. JAMA. 2018;320(14):1455–1463. PMID: 30304428 https://doi.org/10.1001/jama.2018.14618</mixed-citation><mixed-citation xml:lang="en">Dellinger RP, Bagshaw SM, Antonelli M, Foster DM, Klein DJ, Marshall JC, et al.; EUPHRATES Trial Investigators. Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients with Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial. JAMA. 2018;320(14):1455–1463. PMID: 30304428 https://doi.org/10.1001/jama.2018.14618</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Pais de Barros JP, Gautier T, Sali W, Adrie C, Choubley H, Charron E, et al.; Quantitative lipopolysaccharide analysis using HPLC/MS/MS and its combination with the limulus amebocyte lysate assay. J Lipid Res. 2015;56(7):1363–1369. PMID: 26023073 https://doi.org/10.1194/jlr. D059725.</mixed-citation><mixed-citation xml:lang="en">Pais de Barros JP, Gautier T, Sali W, Adrie C, Choubley H, Charron E, et al.; Quantitative lipopolysaccharide analysis using HPLC/MS/MS and its combination with the limulus amebocyte lysate assay. J Lipid Res. 2015;56(7):1363–1369. PMID: 26023073 https://doi.org/10.1194/jlr.D059725.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Quadrini KJ, Patti-Diaz L, Maghsoudlou J, Cuomo J, Hedrick MN, McCloskey TW. A flow cytometric assay for HLA-DR expression on monocytes validated as a biomarker for enrollment in sepsis clinical trials. Cytometry B Clin Cytom. 2021;100(1):103–114. PMID: 33432735 https://doi.org/10.1002/cyto.b.21987</mixed-citation><mixed-citation xml:lang="en">Quadrini KJ, Patti-Diaz L, Maghsoudlou J, Cuomo J, Hedrick MN, McCloskey TW. A flow cytometric assay for HLA-DR expression on monocytes validated as a biomarker for enrollment in sepsis clinical trials. Cytometry B Clin Cytom. 2021;100(1):103–114. PMID: 33432735 https://doi.org/10.1002/cyto.b.21987</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009;301(23):2445–2452. PMID: 19531784 https://doi.org/10.1001/jama.2009.856</mixed-citation><mixed-citation xml:lang="en">Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009;301(23):2445–2452. PMID: 19531784 https://doi.org/10.1001/jama.2009.856</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Payen DM, Guilhot J, Launey Y, Lukaszewicz AC, Kaaki M, Veber B, et al.; ABDOMIX Group. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med. 2015;41(6):975–984. PMID: 25862039 https://doi.org/10.1007/s00134-015-3751-z</mixed-citation><mixed-citation xml:lang="en">Payen DM, Guilhot J, Launey Y, Lukaszewicz AC, Kaaki M, Veber B, et al.; ABDOMIX Group. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med. 2015;41(6):975–984. PMID: 25862039 https://doi.org/10.1007/s00134-015-3751-z</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Rey S, Kulabukhov VM, Popov A, Nikitina O, Berdnikov G, Magomedov M, et al. Hemoperfusion using the LPS-selective mesoporous polymeric adsorbent in septic shock: a multicenter randomized clinical trial. Shock. 2023;59(6):846–854. PMID: 37018802 https://doi.org/10.1097/SHK.0000000000002121</mixed-citation><mixed-citation xml:lang="en">Rey S, Kulabukhov VM, Popov A, Nikitina O, Berdnikov G, Magomedov M, et al. Hemoperfusion using the LPS-selective mesoporous polymeric adsorbent in septic shock: a multicenter randomized clinical trial. Shock. 2023;59(6):846–854. PMID: 37018802 https://doi.org/10.1097/SHK.0000000000002121</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Nakamura К, Okazaki T, Tampo A, Mochizuki K, Kanda N, Ono T, et al. The polymyxin-B direct hemoperfusion OPTimal Initiation timing with Catecholamine PMX-OPTIC study: A multicenter retrospective observational study. Artif Organs. 2024 Sep 18. PMID: 39291793 https://doi.org/10.1111/aor.14865 Online ahead of print.</mixed-citation><mixed-citation xml:lang="en">Nakamura К, Okazaki T, Tampo A, Mochizuki K, Kanda N, Ono T, et al. The polymyxin-B direct hemoperfusion OPTimal Initiation timing with Catecholamine PMX-OPTIC study: A multicenter retrospective observational study. Artif Organs. 2024 Sep 18. PMID: 39291793 https://doi.org/10.1111/aor.14865 Online ahead of print.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Lee JH, Han WH, Im H, Kim JH. Effects of Early Initiation of Polymyxin B Hemoperfusion Therapy in Patients with Cancer with Refractory Septic Shock. J Clin Med. 2024;13(4):1009. PMID: 38398322 https://doi.org/10.3390/jcm13041009</mixed-citation><mixed-citation xml:lang="en">Lee JH, Han WH, Im H, Kim JH. Effects of Early Initiation of Polymyxin B Hemoperfusion Therapy in Patients with Cancer with Refractory Septic Shock. J Clin Med. 2024;13(4):1009. PMID: 38398322 https://doi. org/10.3390/jcm13041009</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Fujimori К, Tarasawa К, Fushimi К. Effectiveness of polymyxin B hemoperfusion for sepsis depends on the baseline SOFA score: a nationwide observational study. Ann Intensive Care. 2021;11(1):141. PMID: 34568980 https://doi.org/10.1186/s13613-021-00928-z</mixed-citation><mixed-citation xml:lang="en">Fujimori К, Tarasawa К, Fushimi К. Effectiveness of polymyxin B hemoperfusion for sepsis depends on the baseline SOFA score: a nationwide observational study. Ann Intensive Care. 2021;11(1):141. PMID: 34568980 https://doi.org/10.1186/s13613-021-00928-z</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Osawa I, Goto T, Kudo D, Hayakawa M, Yamakawa K, Kushimoto S, et al. Targeted therapy using polymyxin B hemadsorption in patients with sepsis: a post-hoc analysis of the JSEPTIC-DIC study and the EUPHRATES trial. Crit Care. 2023;27(1):245. PMID: 37344804 https://doi.org/10.1186/s13054-023-04533-3</mixed-citation><mixed-citation xml:lang="en">Osawa I, Goto T, Kudo D, Hayakawa M, Yamakawa K, Kushimoto S, et al. Targeted therapy using polymyxin B hemadsorption in patients with sepsis: a post-hoc analysis of the JSEPTIC-DIC study and the EUPHRATES trial. Crit Care. 2023;27(1):245. PMID: 37344804 https://doi.org/10.1186/s13054-023-04533-3</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Payen D, Dupuis C, Deckert V, Pais de Barros JP, Rérole AL, Lukaszewicz AC, et al. Endotoxin Mass Concentration in Plasma Is Associated with Mortality in a Multicentric Cohort of PeritonitisInduced Shock. Front Med (Lausanne). 2021:8:749405. PMID: 34778311 https://doi.org/10.3389/fmed.2021.749405 eCollection 2021</mixed-citation><mixed-citation xml:lang="en">Payen D, Dupuis C, Deckert V, Pais de Barros JP, Rérole AL, Lukaszewicz AC, et al. Endotoxin Mass Concentration in Plasma Is Associated with Mortality in a Multicentric Cohort of PeritonitisInduced Shock. Front Med (Lausanne). 2021:8:749405. PMID: 34778311 https://doi.org/10.3389/fmed.2021.749405 eCollection 2021</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Cotoia A, Parisano V, Mariotti PS, Lizzi V, Netti GS, Ranieri E, et al. Kinetics of different blood biomarkers during Polymyxin-B extracorporeal hemoperfusion in abdominal sepsis. Blood Purif. 2024;53(7):574–582. PMID: 38653211 https://doi.org/10.1159/000538870</mixed-citation><mixed-citation xml:lang="en">Cotoia A, Parisano V, Mariotti PS, Lizzi V, Netti GS, Ranieri E, et al. Kinetics of different blood biomarkers during Polymyxin-B extracorporeal hemoperfusion in abdominal sepsis. Blood Purif. 2024;53(7):574–582. PMID: 38653211 https://doi.org/10.1159/000538870</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Mengos AE, Gastineau DA, Gustafson MP. The CD14+HLA-DRlo/ neg Monocyte: An Immunosuppressive Phenotype That Restrains Responses to Cancer Immunotherapy. Front Immunol. 2019:10:1147. PMID: 31191529 https://doi.org/10.3389/fimmu.2019.01147 eCollection 2019.</mixed-citation><mixed-citation xml:lang="en">Mengos AE, Gastineau DA, Gustafson MP. The CD14+HLA-DRlo/ neg Monocyte: An Immunosuppressive Phenotype That Restrains Responses to Cancer Immunotherapy. Front Immunol. 2019:10:1147. PMID: 31191529 https://doi.org/10.3389/fimmu.2019.01147 eCollection 2019.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Papadopoulos P, Pistiki A, Theodorakopoulou M, Christodoulopoulou T, Damoraki G, Goukos D, et al. Immunoparalysis: Clinical and immunological associations in SIRS and severe sepsis patients. Cytokine. 2017;92:83–92. PMID: 28119177 https://doi.org/10.1016/j.cyto.2017.01.012</mixed-citation><mixed-citation xml:lang="en">Papadopoulos P, Pistiki A, Theodorakopoulou M, Christodoulopoulou T, Damoraki G, Goukos D, et al. Immunoparalysis: Clinical and immunological associations in SIRS and severe sepsis patients. Cytokine. 2017;92:83–92. PMID: 28119177 https://doi.org/10.1016/j.cyto.2017.01.012</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Volk HD, Reinke P, Krausch D, Zuckermann H, Asadullah K, Muller JM, et al. Monocyte deactivation–rationale for a new therapeutic strategy in sepsis. Intensive Care Med. 1996;22 (Suppl. 4):S474–481. PMID: 8923092 https://doi.org/10.1007/BF01743727</mixed-citation><mixed-citation xml:lang="en">Volk HD, Reinke P, Krausch D, Zuckermann H, Asadullah K, Muller JM, et al. Monocyte deactivation–rationale for a new therapeutic strategy in sepsis. Intensive Care Med. 1996;22 (Suppl. 4):S474–481. PMID: 8923092 https://doi.org/10.1007/BF01743727</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Лаврик И., Краммер П. Решение «Жизнь-или-смерть» в системе CD95: основные про- и антиапоптозные модуляторы. Acta Naturae (русскоязычная версия). 2009;(1):80–83.</mixed-citation><mixed-citation xml:lang="en">Lavrik IN, Krammer PH. Life and Death Decisions in the CD95 System: Main Pro- and Anti-Apoptotic Modulators. Acta Naturae. 2009;1(1):80– 83. PMID: 22649588</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Yoo H, Lee JY, Park J, Suh GY, Jeon K. Association of Plasma Levels of Fas Ligand with Severity and Outcome of Sepsis. Shock. 2021;56(4):544– 550. PMID: 33577245 https://doi.org/10.1097/SHK.0000000000001753</mixed-citation><mixed-citation xml:lang="en">Yoo H, Lee JY, Park J, Suh GY, Jeon K. Association of Plasma Levels of Fas Ligand with Severity and Outcome of Sepsis. Shock. 2021;56(4):544– 550. PMID: 33577245 https://doi.org/10.1097/SHK.0000000000001753</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Asbun-Bojalil J, Huerta-Yepez S, Vega M. Correlation of the expression of YY1 and Fas cell surface death receptor with apoptosis of peripheral blood mononuclear cells, and the development of multiple organ dysfunction in children with sepsis. Mol Med Rep. 2017;15(5):2433– 2442. PMID: 28447715 https://doi.org/10.3892/mmr.2017.6310</mixed-citation><mixed-citation xml:lang="en">Asbun-Bojalil J, Huerta-Yepez S, Vega M. Correlation of the expression of YY1 and Fas cell surface death receptor with apoptosis of peripheral blood mononuclear cells, and the development of multiple organ dysfunction in children with sepsis. Mol Med Rep. 2017;15(5):2433– 2442. PMID: 28447715 https://doi.org/10.3892/mmr.2017.6310</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
